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Abstract
We characterized the molecular genetic consequences
of a balanced chromosome translocation t(8;22)(p21;
q12), which occurred as the sole cytogenetic aberration
in short-term cultured cells from an intrathoracic ma-
ture teratoma in a 15-year-old girl. Fluorescence in situ
hybridization and reverse transcription–polymerase
chain reaction disclosed that t(8;22) resulted in the
fusion of the genes PPP2R2A and CHEK2, with an
inserted fragment belonging to class I endogenous
retrovirus–related sequences at the junction. Sequenc-
ing of the two genes did not reveal any additional mu-
tation. None of the three detected PPP2R2A/CHEK2
fusion transcripts resulted in an in-frame PPP2R2A/
CHEK2 chimerical open reading frame; however, in all of
them, the known open reading frame of CHEK2was pre-
served. Thus, promoter swapping leading toderegulated
CHEK2 expression would be the most likely oncogenic
mechanism. Whereas inactivating mutations of CHEK2
previously have been described in a variety of sporadic
tumors and in inherited cancer-predisposing syn-
dromes, PPP2R2A, encoding a regulatory subunit of the
multimeric enzyme phosphatase 2, has not been directly
implicated in tumorigenesis. Our findings suggest that
deregulation of CHEK2 and/or PPP2R2A is of pathoge-
netic importance in at least a subset of germ cell tumors.
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Introduction
Mature teratomas are germ cell neoplasms composed of
adult-type tissues derived from at least two embryonic
layers [1,2]. Most mature teratomas present congenitally in
the sacrococcygeal region or within the ovaries or testes of
adolescents, but they may occur throughout the body at any
age. As the development of teratomas resembles embryo-
genesis in various aspects, they have been used as a model
system to study both embryonic and tumorigenic processes.
Little is known about the genetic mechanisms involved
in the pathogenesis of mature teratomas. In contrast tomore
aggressive subtypes of germ cell tumors, which typically have
aneuploid karyotypes with a gain of the short arm of chro-
mosome 12 as the most common feature, mature teratomas
often display normal karyotype on cytogenetic analysis, and no
consistent pattern of chromosomal gains or losses has been
disclosed by comparative genomic hybridization [3,4]. Further-
more, neither in mature teratomas nor in germ cell tumors, in
general, has any recurrent, acquired, tumor-specific, balanced
chromosome rearrangement been detected. Recently, how-
ever, a constitutional t(12;15)(q13;q25), resulting in the fusion
of the genes SENP1 and MESDC2, was identified in a patient
with infantile teratoma [5].
We have previously reported cytogenetic findings in two
teratomas, one of which displayed a balanced translocation t(8;
22)(p21;q12) [6]. In the present study, precise mapping of break-
points was carried out by fluorescence in situ hybridization
(FISH) on metaphase spreads from this tumor. Based on FISH
results implicating a fusion between the PPP2R2A and CHEK2
genes, further molecular investigations were undertaken.
Materials and Methods
Patient
A 15-year-old girl was admitted to a hospital because of viral
meningoencephalitis. Due to increasing respiratory difficulty,
X-ray and computed tomography scan of the thorax were
performed, revealing a large mediastinal tumor. On cytologic
analysis of cells obtained from a fine-needle aspiration biopsy
of the tumor, no malignant cells were identified, and the tumor
was tentatively diagnosed as cystic mature teratoma. After the
patient had recovered from meningoencephalitis, the medias-
tinal tumor was radically excised. Histologic examination of
the excised tumor demonstrated a mature teratoma without
malignant features. Postoperatively, the patient had a slow
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recovery but remained disease-free for 6 years, after which
she was lost to follow-up.
G-banding
Cytogenetic analysis was performed on two occasions
[6]. On diagnosis, both a bone marrow sample and tumor
cells derived from the fine-needle aspiration biopsy of the
mediastinal mass were analyzed. All 25 metaphase cells
from the bone marrow sample showed normal female kar-
yotype, whereas short-term cultured cells from the fine-
needle aspiration biopsy displayed a balanced translocation
t(8;22)(p21;q12) as the sole change in 9 of 14 metaphases;
the remaining five mitoses were normal. Cytogenetic inves-
tigation of the radically excised tumor showed t(8;22) as the
sole change in all 25 metaphase spreads analyzed.
FISH
Vital frozen cells stored in liquid nitrogen were thawed and
plated in culture flasks with RPMI 1640 medium supple-
mented with 17% serum and antibiotics. Chromosome prep-
arations for FISH were harvested at passages 2 and 4, as
described [7]. To confirmwhether the cells still carried t(8;22),
they were also subjected to conventional G-banding analysis.
The breakpoint on chromosome 22 was first inves-
tigated using commercially available probes for the EWSR1
(22q12.2) and BCR (22q11.23) genes (Vysis, Downers
Grove, IL). To further characterize the two chromosomal
breakpoints, 32 BAC clones (16 spanning 8p12–8p21 and
16 spanning 22q11.2–22q12.2) were selected based on
their location on the NCBI Map Viewer (http://www.ncbi.nlm.
nih.gov/cgi-bin/Entreez/map-search, 2005) and the UCSC
Human Genome Browser Gateway (http://genome.ucsc.
edu/cgi-bin/hgGateway). Clones were propagated, and
DNA was extracted by standard methods [8]. BAC DNA
was labeled by random hexamer priming (megaprime DNA
labeling system; Amersham, Buckinghamshire, UK) with
a single fluorochrome or ligand (i.e., biotin-16-dUTP, Cy3-
dCTP, digoxigenin-11-dUTP, or FluorX-dCTP). Labeled
probes were purified, precipitated, and dissolved in a stan-
dard hybridization solution. Slides and probes were dena-
tured simultaneously by incubation on a hot plate at 72jC.
After overnight hybridization at 37jC in a humidified cham-
ber, the slides were washed at 74jC in 0.4 SSC for 2 min-
utes, DAPI-stained, and analyzed.
Reverse Transcription–Polymerase Chain Reaction
(RT-PCR) and Sequence Analyses
Total RNA was extracted from cultured cells using Trizol
reagent, according to the manufacturer’s instructions (Invi-
trogen, Carlsbad, CA). cDNA synthesis was conducted
using 5 mg of total RNA in a 20-ml reaction mixture containing
1 first-strand buffer, 10 mM DTT, 1 mM of each deoxy-
nucleoside triphosphate (dNTP), 20 U of RNAse inhibitor
(RNA guard; Amersham Biosciences, Piscataway, NJ),
500 pmol of random hexamers, and 200 U of M-MLV reverse
transcriptase (Invitrogen). The reaction was carried out at
37jC for 60 minutes, heated at 65jC for 5 minutes, and then
kept at 4jC until analysis. PCR amplifications were per-
formed using 1 ml of cDNA as template in a final volume
of 50 ml containing 1 PCR buffer, 0.2 mM of each dNTP,
1.25 mM MgCl2, 0.5 mM of each forward primer and reverse
primer, and 1 U of Platinum Taq DNA polymerase (Invitro-
gen), and run on a PCT-200 DNA Engine (MJ Research,
Waltham, MA).
Primers specific forCHEK2 and PPP2R2Awere designed
to detect possible fusion transcripts (Table 1). Transcripts
were amplified using initial denaturation for 5 minutes at
94jC; 30 cycles of 1 minute at 94jC, 1 minute at 60jC, and
1 minute at 72jC; and final extension for 10 minutes at 72jC.
Amplified fragments were run on a 1.6% agarose gel stained
with ethidium bromide, purified using a QIAquick gel extrac-
tion kit (Qiagen, Hilden, Germany), and directly sequenced
with the dideoxy procedure using an ABI Prism BigDye
terminator cycle sequencing ready reaction kit (Applied Bio-
systems, Foster City, CA) on the Applied Biosystems Model
3100-Avant DNA sequencing system. BLAST software
(http://www.ncbi.nlm.nih.gov/blast) was used for the analysis
of CHEK2 and PPP2R2A sequence data.
Screening for Additional CHEK2 and PPP2R2A Mutations
To search for additional CHEK2 mutations, PCR amplifi-
cations of exons 4 to 9 were performed using 160 ng of
genomic DNA as template in a volume of 50 ml containing 1
PCR buffer, 0.8 mM dNTP, 1.25 mM MgCl2, 0.5 mM of each
forward primer and reverse primer, and 1 U of Platinum Taq
DNA polymerase (Invitrogen). The annealing temperature
for exons 4 to 9 was 58jC. PCR reactions were carried out
on a PCT-200 DNA Engine (MJ Research) with initial dena-
turation for 5 minutes at 94jC; 30 cycles of 1 minute at 94jC,
1 minute at 58jC, and 1 minute at 72jC; and final extension
for 5 minutes at 72jC and for 2 minutes at 26jC. Amplified
fragments were run on a 1.6% agarose gel stained with
ethidium bromide, purified using the QIAquick gel extraction
kit (Qiagen), and sequenced as described above.
For the analysis of exons 10 to 14, the methods described
by Sodha et al. [9] were used. Long-range PCR across exons
10 to 14 ofCHEK2was performed, and the product was used
to individually amplify exons 10 to 14.
To search forPPP2R2Amutations, exons 1 to 10were am-
plified by PCR and sequenced as described above. Primers
for the sequencing of CHEK2 and PPP2R2A are available
at request.
The BLAST software (http://www.ncbi.nlm.nih.gov/blast)
was used for the mutational analysis of CHEK2 and
PPP2R2A.
Table 1. Primers for RT-PCR and Direct Sequencing.
Primer Sequence
PPP2R2A-242F GTCTCCGCTTCCTGAACTCACCC
PPP2R2A-286F CCATGTTGCGCTGCAAATGGT
CHEK2-294R TCCTCAGGTTCTTGGTCCTCAGGA
CHEK2-473R GGTGCCTCACACCTCTTATCCCAG
CHEK2-686R ACAAAGGTTCCATTGCCACTGTGAT
CHEK2-982R AGAGCTGGGTCTGCCTCTCTTGC
CHEK2-906R CATGTTTTCCTCTCGAAAGCCAGC
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Results
FISH Characterization of Breakpoints in 8p21 and 22q12
All metaphase cells harvested from passages 2 and 4
carried t(8;22) (Figure 1A). With the use of probes for the
EWSR1 (22q12.2) and BCR genes (22q11.23), the chromo-
somal breakpoint in chromosome 22 was narrowed down
to the 6-Mb region between these two loci. Subsequently,
16 BAC clones within this region were selected for further
FISH, and the hybridization of one of these clones (i.e.,
RP11-444G7, covering the CHEK2 locus) showed split sig-
nals (Figure 1B). The breakpoint in chromosome 8 was then
investigated by the use of 16 BAC clones spanning 8p12–
p21. The hybridization of probe RP11-795G8 (containing the
PPP2R2A locus) resulted in split signals (Figure 1C).
Detection and Characterization of PPP2R2A/CHEK2
Fusion Transcripts
RT-PCR with various PPP2R2A and CHEK2 primer com-
binations was carried out to detect fusion transcripts. The use
of PPP2R2A forward primer PPP2R2A-242F and CHEK2
reverse primer CHEK2-982R gave rise to three amplified
fragments, suggesting the presence of a PPP2R2A/CHEK2
fusion gene (Figure 2). The three fusion transcripts were then
analyzed by direct sequencing with the use of several differ-
ent PPP2R2A forward primers and CHEK2 reverse primers
for further characterization of the fusion breakpoint. Further-
more, a fourth fainter band was seen, presumably represent-
ing another splice variant of the fusion product. This band,
however, was not sequenced.
In fusion transcripts 1 and 2, exon 2 of PPP2R2A (NM_
002717) was fused with exon 4 of CHEK2 (NM_007194.3)
(Figures 2 and 3), whereas in transcript 3, exon 2 of
PPP2R2A was fused with exon 5 of CHEK2. In all three
transcripts, inserted fragments were found at the junctions
(Figure 3). In transcript 1, a 231-bp DNA fragment was in-
serted between exon 2 of PPP2R2A and exon 4 of CHEK2.
In transcripts 2 and 3, a 98-bp fragment was inserted be-
tween the two genes. BLAST analysis revealed that the
inserted fragment corresponded to nucleotide positions
22187 to 21953 (231-bp insert) and 22187 to 22086 (98-bp
insert) of AL023494 (RP3-366L4), which flanks the telomeric
5V part of CHEK2. Using a repeat masker engine (http://www.
repeatmasker.org), the inserts were found to belong to class I
endogenous retrovirus (ERV)–related sequences [10].
None of the three amplified transcripts resulted in a chi-
meric in-frame PPP2R2A/CHEK2 open reading frame. In all
detected fusion transcripts, the first 28 translated amino acids
of PPP2R2A were followed by amino acids GQ and the
terminal codon TGA.
Sequencing of CHEK2 exons 4 to 14 and of PPP2R2A
exons 1 to 10 did not reveal any additional mutations.
Discussion
In the present study, we used FISH and RT-PCR to charac-
terize a balanced translocation t(8;22) in a mediastinal ma-
ture teratoma and showed that this translocation leads to
the creation of a novel fusion gene PPP2R2A/CHEK2. The
fact that t(8;22) was the sole chromosomal change in this
tumor makes it reasonable to assume that it was important in
pathogenesis. Although the t(8;22) seen in our case has not
been described before, it should be emphasized that only a
few teratomas, in general, and pediatric extragonadal mature
teratomas, in particular, have been cytogenetically analyzed.
It should also be noted that various structural rearrange-
ments with breakpoints in 8p or 22q have been reported
in teratomas [11].
The mechanism by which t(8;22) may promote tumor de-
velopment is unclear. All detected PPP2R2A/CHEK2 fusion
transcripts were out of frame, making it unlikely that they
would be translated into proper fusion proteins. However,
transcripts 1 and 2 preserve the known CHEK2 open reading
Figure 1. (A) Partial karyogram showing a reciprocal translocation t(8;22)(p21;
q12). Arrows indicate breakpoints. (B) Metaphase cell hybridized with the BAC
probe RP11-444G7 (covering the CHEK2 locus; green signals). Arrows
indicate split signals on derivative chromosomes 8 and 22. (C) Metaphase cell
hybridized with BAC probes RP11-795G8 (covering the PPP2R2A locus;
green signals) and RP11-426J12 (mapping to the centromeric side of the
breakpoint on chromosome 8; red signal). Arrows indicate split signals for
RP11-795G8 on the derivative chromosomes 8 and 22.
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frame, which begins at exon 4, suggesting that one con-
sequence may be aberrant expression of CHEK2 from the
PPP2R2A promoter. Such transcriptional deregulation
through juxtapositioning with an ectopic promoter (an onco-
genic mechanism known as promoter swapping) has been
well documented for several other solid tumors, including
pleomorphic adenoma of the salivary glands, lipoblastoma,
and aneurysmal bone cyst [12–14]. Although this seems
to be themost likely mechanism in the present case, it should
be noted that, theoretically, the transcripts could be trans-
lated into the first 28 amino acids of PPP2R2A followed by
two amino acids from the inserted ERV sequence, and it
cannot be excluded that this chimera could be of patho-
genetic importance.
CHEK2, which encodes a checkpoint kinase, is consid-
ered a tumor-suppressor gene based on its known role in
cellular responses to DNA double-strand breaks, the finding
of biallelic inactivating mutations in various sporadic tumors,
and epidemiological data showing that certain constitutional
mutations confer increased risk for breast cancer, for ex-
ample [15–17]. In response to double-strand DNA breaks,
CHEK2 becomes activated and phosphorylates various sub-
strates, including CDC25A, CDC25C, BRCA1, E2F1, PML,
PLK3, and TP53, thereby promoting a variety of cellular
responses, such as cell cycle arrest, apoptosis, and DNA re-
pair. Somatic inactivating mutations of CHEK2 have been
found in small subsets of diverse types of sporadic human
malignancies, including osteosarcomas, lymphomas, and
carcinomas of the breast, vulva, urinary bladder, and ovary,
but they seem to be rare in pediatric cancer [18]. Themajority
of somatic mutations are missense or truncating mutations
clustered in three domains of the CHEK2 protein: the N-
terminal SQ/TQ–rich regulatory domain, the protein–protein
interaction FHA domain, and the C-terminal catalytic domain
[16]. 1100delC mutation, which was first reported in a subset
of patients with Li-Fraumeni syndrome, and other constitu-
tional variants are overrepresented in families predisposed
to breast cancer and other malignancies [19–21]. It is also
well known that CHEK2 is subject to extensive alternative
splicing, with close to 90 splice variants being detected in one
study [22]. At present, it is not known whether this complex
alternative splicing could influence tumorigenesis. However,
the finding of at least three splice variants of the PPP2R2A/
CHEK2 fusion product in the present teratoma is well in line
with previously reported data for CHEK2.
PPP2R2A, however, has not been directly implicated in
tumorigenesis. The PPP2R2A protein is a regulatory subunit
of the protein phosphatase 2 (PP2A) enzyme, a highly con-
served Ser/Thr phosphatase that regulates cell growth and
differentiation through a variety of cellular processes, includ-
ing signal transduction, DNA replication, apoptosis, and cell
cycle progression [23–25]. The PP2A holoenzyme consists
of a common dimeric core of a catalytic (C) subunit and a
structural (A) subunit, which, in turn, may be associated with
a variety of regulatory (B) subunits influencing the sub-
cellular localization and substrate specificity of the phospha-
tase. Seventy-five different dimeric and trimeric PP2A
holoenzymes can thus be generated [23,25]. The PPP2R2A
gene encodes an a isoform (aka B55a or PR55a) of the regu-
latory B55 subunit family. Drosophila melanogaster mutants
carrying an inactivated B55a/PR55a gene show an ab-
normal anaphase distribution of chromosomes; in mammalian
cells, the B55a/PR55a subunit seems to be essential for the
dephosphorylation of cytoplasmic intermediate filaments
[26,27]. Furthermore, PP2A is thought to prevent premature
entry into mitosis by negatively regulating CDC2 by keeping
CDC25C in a dephosphorylated low-activity state [28]; seem-
ingly, the dephosphorylation/inhibition of CDC25C is exerted
by a form of PP2A containing the regulatory subunit B55a [29].
Other support for a suppressor function of PP2A in tumori-
genesis stems from the observation that the tumor-promoting
agent okadaic acid is a potential inhibitor of PP2A [30].
Additionally, mutations in PPP2R1A and PPP2A1B genes,
encoding the PP2A subunits RP65a and RP65b, respectively,
have been detected in melanomas and carcinomas of the
lung, breast, and colon [25,31,32]. Of particular interest, it was
Figure 2. Analysis of the PPP2R2A/CHEK2 fusion transcripts. M: 100-bp DNA ladder. Lane 1: No fusion transcript was found while using the forward primer
CHEK2-82F and the reverse primer PPP2R2A-956R. Lane 2: Blank. Lane 3: Three fusion transcripts were detected with the forward primer PPP2R2A-242F and
the reverse primer CHEK2-982R.
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recently shown that PP2A can dephosphorylate and inactivate
CHEK2 and, vice versa, that CHEK2 can phosphorylate the B
subunit of PP2A, thereby increasing its activity [33].
The present study showed that the outcome of t(8;22),
found as the sole chromosome aberration in a mature tera-
toma, is the fusion of PPP2R2A and CHEK2—the first
acquired fusion gene to be detected in germ cell tumors. In
the majority of cases, previous identification of gene fusions
in human malignancies has been guided by the finding of
balanced chromosome rearrangements in short-term cul-
tured tumor cells, and it has been hypothesized that the
present relative lack of known fusion genes in certain tumor
types, such as epithelial malignancies and germ cell tumors,
might be partly explained by the small number of such tumors
Figure 3. Complete nucleotide sequence of PPP2R2A/CHEK2 chimeric transcript 1 detected by RT-PCR. The primers PPP2R2A-242F and CHEK2-982R are
underlined. Arrowheads indicate breakpoints, and vertical lines indicate exon boundaries. The inserted DNA between exon 2 of PPP2R2A and exon 4 of CHEK2 is
a repetitive sequence from chromosome 22, which belongs to type 1 of ERV-related sequences. Sequence in bold (part of the inserted DNA) is absent in type 2
chimeric transcript. Sequence in brackets is not present in type 3 of the PPP2R2A/CHEK2 cDNA fragment (part of inserted sequence and exon 4 of CHEK2).
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that have been properly analyzed by chromosome banding
techniques [34]. In line with this reasoning, it was recently
shown that a large fraction of prostate carcinomas carries
subtle chromosome rearrangements, leading to highly re-
current fusion genes [35]. Whether the presently detected
PPP2R2A/CHEK2 fusion is a common and tumor-specific
event needs to be analyzed in a larger series of teratomas. In
addition, if the essential molecular outcome in the present
case were deregulation of CHEK2 and/or PPP2R2A rather
than creation of a specific fusion transcript, it might be worth-
while to study the expression patterns of these genes in germ
cell neoplasms.
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